Research ExplorerPublicationsSurvival rates with external beam radiation therapy in newly...

Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients

Standard

Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. / Wenzel, Mike; Collà Ruvolo, Claudia; Würnschimmel, Christoph; Nocera, Luigi; Tian, Zhe; Saad, Fred; Briganti, Alberto; Tilki, Derya; Graefen, Markus; Becker, Andreas; Roos, Frederik; Mandel, Philipp; Chun, Felix K H; Karakiewicz, Pierre I.

In: PROSTATE, Vol. 82, No. 1, 01.2022, p. 78-85.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wenzel, M, Collà Ruvolo, C, Würnschimmel, C, Nocera, L, Tian, Z, Saad, F, Briganti, A, Tilki, D, Graefen, M, Becker, A, Roos, F, Mandel, P, Chun, FKH & Karakiewicz, PI 2022, 'Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients', PROSTATE, vol. 82, no. 1, pp. 78-85. https://doi.org/10.1002/pros.24249

APA

Wenzel, M., Collà Ruvolo, C., Würnschimmel, C., Nocera, L., Tian, Z., Saad, F., Briganti, A., Tilki, D., Graefen, M., Becker, A., Roos, F., Mandel, P., Chun, F. K. H., & Karakiewicz, P. I. (2022). Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. PROSTATE, 82(1), 78-85. https://doi.org/10.1002/pros.24249

Vancouver

Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Tian Z, Saad F et al. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. PROSTATE. 2022 Jan;82(1):78-85. https://doi.org/10.1002/pros.24249

Bibtex

@article{15ee589d14114bf7a55b9f54e16aa22a,
title = "Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients",
abstract = "BACKGROUND: The survival benefit of primary external beam radiation therapy (EBRT) has never been formally tested in elderly men who were newly diagnosed with metastatic prostate cancer (mPCa). We hypothesized that elderly patients may not benefit of EBRT to the extent as younger newly diagnosed mPCa patients, due to shorter life expectancy.METHODS: We relied on Surveillance, Epidemiology and End Results (2004-2016) to identify elderly newly diagnosed mPCa patients, aged >75 years. Kaplan-Meier, univariable and multivariable Cox regression models, as well as Competing Risks Regression models tested the effect of EBRT versus no EBRT on overall mortality (OM) and cancer-specific mortality (CSM).RESULTS: Of 6556 patients, 1105 received EBRT (16.9%). M1b stage was predominant in both EBRT (n = 823; 74.5%) and no EBRT (n = 3908; 71.7%, p = 0.06) groups, followed by M1c (n = 211; 19.1% vs. n = 1042; 19.1%, p = 1) and M1a (n = 29; 2.6% vs. n = 268; 4.9%, p < 0.01). Median overall survival (OS) was 23 months for EBRT and 23 months for no EBRT (hazard ratio [HR]: 0.97, p = 0.6). Similarly, median cancer-specific survival (CSS) was 29 months for EBRT versus 30 months for no EBRT (HR: 1.04, p = 0.4). After additional multivariable adjustment, EBRT was not associated with lower OM or lower CSM in the entire cohort, as well as after stratification for M1b and M1c substages.CONCLUSIONS: In elderly men who were newly diagnosed with mPCa, EBRT does not affect OS or CSS. In consequence, our findings question the added value of local EBRT in elderly newly diagnosed mPCa patients.",
author = "Mike Wenzel and {Coll{\`a} Ruvolo}, Claudia and Christoph W{\"u}rnschimmel and Luigi Nocera and Zhe Tian and Fred Saad and Alberto Briganti and Derya Tilki and Markus Graefen and Andreas Becker and Frederik Roos and Philipp Mandel and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2021 The Authors. The Prostate published by Wiley Periodicals LLC.",
year = "2022",
month = jan,
doi = "10.1002/pros.24249",
language = "English",
volume = "82",
pages = "78--85",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients

AU - Wenzel, Mike

AU - Collà Ruvolo, Claudia

AU - Würnschimmel, Christoph

AU - Nocera, Luigi

AU - Tian, Zhe

AU - Saad, Fred

AU - Briganti, Alberto

AU - Tilki, Derya

AU - Graefen, Markus

AU - Becker, Andreas

AU - Roos, Frederik

AU - Mandel, Philipp

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

N1 - © 2021 The Authors. The Prostate published by Wiley Periodicals LLC.

PY - 2022/1

Y1 - 2022/1

N2 - BACKGROUND: The survival benefit of primary external beam radiation therapy (EBRT) has never been formally tested in elderly men who were newly diagnosed with metastatic prostate cancer (mPCa). We hypothesized that elderly patients may not benefit of EBRT to the extent as younger newly diagnosed mPCa patients, due to shorter life expectancy.METHODS: We relied on Surveillance, Epidemiology and End Results (2004-2016) to identify elderly newly diagnosed mPCa patients, aged >75 years. Kaplan-Meier, univariable and multivariable Cox regression models, as well as Competing Risks Regression models tested the effect of EBRT versus no EBRT on overall mortality (OM) and cancer-specific mortality (CSM).RESULTS: Of 6556 patients, 1105 received EBRT (16.9%). M1b stage was predominant in both EBRT (n = 823; 74.5%) and no EBRT (n = 3908; 71.7%, p = 0.06) groups, followed by M1c (n = 211; 19.1% vs. n = 1042; 19.1%, p = 1) and M1a (n = 29; 2.6% vs. n = 268; 4.9%, p < 0.01). Median overall survival (OS) was 23 months for EBRT and 23 months for no EBRT (hazard ratio [HR]: 0.97, p = 0.6). Similarly, median cancer-specific survival (CSS) was 29 months for EBRT versus 30 months for no EBRT (HR: 1.04, p = 0.4). After additional multivariable adjustment, EBRT was not associated with lower OM or lower CSM in the entire cohort, as well as after stratification for M1b and M1c substages.CONCLUSIONS: In elderly men who were newly diagnosed with mPCa, EBRT does not affect OS or CSS. In consequence, our findings question the added value of local EBRT in elderly newly diagnosed mPCa patients.

AB - BACKGROUND: The survival benefit of primary external beam radiation therapy (EBRT) has never been formally tested in elderly men who were newly diagnosed with metastatic prostate cancer (mPCa). We hypothesized that elderly patients may not benefit of EBRT to the extent as younger newly diagnosed mPCa patients, due to shorter life expectancy.METHODS: We relied on Surveillance, Epidemiology and End Results (2004-2016) to identify elderly newly diagnosed mPCa patients, aged >75 years. Kaplan-Meier, univariable and multivariable Cox regression models, as well as Competing Risks Regression models tested the effect of EBRT versus no EBRT on overall mortality (OM) and cancer-specific mortality (CSM).RESULTS: Of 6556 patients, 1105 received EBRT (16.9%). M1b stage was predominant in both EBRT (n = 823; 74.5%) and no EBRT (n = 3908; 71.7%, p = 0.06) groups, followed by M1c (n = 211; 19.1% vs. n = 1042; 19.1%, p = 1) and M1a (n = 29; 2.6% vs. n = 268; 4.9%, p < 0.01). Median overall survival (OS) was 23 months for EBRT and 23 months for no EBRT (hazard ratio [HR]: 0.97, p = 0.6). Similarly, median cancer-specific survival (CSS) was 29 months for EBRT versus 30 months for no EBRT (HR: 1.04, p = 0.4). After additional multivariable adjustment, EBRT was not associated with lower OM or lower CSM in the entire cohort, as well as after stratification for M1b and M1c substages.CONCLUSIONS: In elderly men who were newly diagnosed with mPCa, EBRT does not affect OS or CSS. In consequence, our findings question the added value of local EBRT in elderly newly diagnosed mPCa patients.

U2 - 10.1002/pros.24249

DO - 10.1002/pros.24249

M3 - SCORING: Journal article

C2 - 34633102

VL - 82

SP - 78

EP - 85

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 1

ER -